Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYSLTR1 | Q9Y271 | 11/20 | 0.50 |
| ▸ | CYSLTR2 | Q9NS75 | 7/20 | 0.50 |
| ▸ | GPBAR1 | Q8TDU6 | 5/20 | 0.50 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5120063 | 0.74 | CYSLTR1 (0.47) | CYSLTR1CYSLTR2GPBAR1PDE10ACYP1A2 | |
| SCHEMBL1424251 | 0.72 | CYSLTR1 (0.58) | CYSLTR1CYSLTR2GPBAR1PDE10A | |
| SCHEMBL5120017 | 0.72 | CYSLTR1 (0.46) | CYSLTR1CYSLTR2GPBAR1PDE10ACYP1A2 | |
| SCHEMBL725176 | 0.72 | PDE10A (0.54) | CYSLTR1CYSLTR2GPBAR1PDE10ACYP1A2 | |
| SCHEMBL5110283 | 0.72 | FFAR1 (0.47) | CYSLTR1CYSLTR2GPBAR1PDE10ACYP1A2 | |
| SCHEMBL30899711 | 0.71 | CYSLTR1 (0.57) | CYSLTR1CYSLTR2GPBAR1PDE10ACYP1A2 | |
| Iodide SCHEMBL1343671 | 0.70 | PDE10A (0.53) | CYSLTR1CYSLTR2GPBAR1PDE10ACYP1A2 | |
| SCHEMBL29047068 | 0.70 | PDE10A (0.53) | CYSLTR1CYSLTR2GPBAR1PDE10ACYP1A2 | |
| SCHEMBL10544630 | 0.70 | CYSLTR1 (0.84) | CYSLTR1CYSLTR2GPBAR1PDE10ACYP1A2 | |
| SCHEMBL9847314 | 0.70 | CYSLTR1 (0.58) | CYSLTR1CYSLTR2GPBAR1PDE10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080051418-A1 | Arylalkanoic Acid Derivative | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-02-28 | — | — | US | disclosed |
| EP-1829863-A1 | ARYLALKANOIC ACID DERIVATIVE | Takeda Pharmaceutical Company Limited (JP) | 2007-09-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080051418-A1 | Arylalkanoic Acid Derivative | INSR, NPY1R, GPR119 | CYSLTR1 806/4885CYSLTR2 1286/4885GPBAR1 252/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.